CD28/OX40 Bispecific Antibodies for Solid Organ Transplant Rejection Treatment
Summary
The USPTO published patent application US20260092113A1, filed by Bristol-Myers Squibb, covering methods for treating solid organ transplant rejection using CD28/OX40 bispecific antibodies. The application (No. 19237572) claims a multispecific binding protein with a VHH domain targeting CD28 and a VH/VL domain targeting OX40. Inventors include Rami Lissilaa, Benjamin Suratt, and Jessica Voss.
What changed
The USPTO published a patent application for a novel therapeutic approach to solid organ transplant rejection using bispecific antibodies. The invention comprises multispecific binding proteins combining an immunoglobulin single variable domain (VHH) with binding specificity to CD28 and a conventional VH/VL domain targeting OX40, administered to prevent or treat transplant rejection. The application is classified under C07K 16/2818 and C07K 16/2878.
Pharmaceutical and biotechnology companies developing transplant therapeutics should review the application scope for freedom-to-operate considerations. This is a published patent application with no compliance requirements or deadlines; it represents intellectual property filing activity rather than regulatory action.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF SOLID ORGAN TRANSPLANT SUBJECTS WITH CD28/OX40 BISPECIFIC ANTIBODIES
Application US20260092113A1 Kind: A1 Apr 02, 2026
Inventors
Rami LISSILAA, Benjamin SURATT, Jessica VOSS
Abstract
Provided herein are methods for the treatment or prevention of solid organ transplant rejection in a subject in need thereof, comprising administering to the subject a multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40.
CPC Classifications
C07K 16/2818 A61P 37/06 C07K 16/2878 A61K 2039/505 C07K 2317/31 C07K 2317/76 C07K 2317/92
Filing Date
2025-06-13
Application No.
19237572
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.